Independent register of U.S. FDA drug recalls · updated Oct 12, 2026
RxRecalls Get alerts

FDA Drug Recalls

6,161 recalls · Class II, newest first

Class II · Moderate risk

Metronidazole Injection

Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.

Terminated Sterility / contamination Claris Lifesciences Inc NDC 36000-001-24 D-0616-2017
Class II · Moderate risk

Levofloxacin Injection in 5% Dextrose

Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.

Terminated Sterility / contamination Claris Lifesciences Inc NDC 36000-048-24 D-0615-2017
Class II · Moderate risk

Fluconazole Injection

Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.

Terminated Sterility / contamination Claris Lifesciences Inc NDC 36000-003-06 D-0614-2017
Class II · Moderate risk

Ciprofloxacin in Dextrose

Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.

Terminated Sterility / contamination Claris Lifesciences Inc NDC 36000-009-24 D-0613-2017
Class II · Moderate risk

Dorama-Neo

Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.

Terminated Sterility / contamination Sato Pharmaceutical Inc. NDC 49873-020-01 D-0856-2017
Class II · Moderate risk

Sato Clear

Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.

Terminated Sterility / contamination Sato Pharmaceutical Inc. NDC 49873-044-01 D-0855-2017
Class II · Moderate risk

Optic Splash

Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.

Terminated Sterility / contamination Sato Pharmaceutical Inc. NDC 49873-501-01 D-0854-2017

Recalls by year